Small Molecule Drugs and Peptide Drugs Innovation Summit
2024year3month21 - 22Date, hosted by Shanghai Kaimo Information Consulting Co., Ltd.SIT 2024The 6th Small Molecule and Peptide Drug Innovation Summit grandly opened. The conference content focused on the innovative development, project establishment strategies, production, andMAHTranslational medicine, win-win cooperationPROTACCovalent inhibitors,PPIConformational inhibitors, peptide conjugates, peptide weight loss drugsAIandCADDAssisting in new drug development and other new technologies, crossing over hotspots in small molecule drug research and development, and providing an overview of current trends in chemical innovative drug research and development.
This conference brings together half of the industry's talents in small molecule drugs and peptide drugs, working together70Remaining speakers, attracting over1,200Industry peers attended the event, committed to breaking the industry's closed loop, promoting innovative and diversified development, and facilitating the healthy development of the industry's industrial chain.
As a media partner for this conference, Frost & SullivanFrost & SullivanChen Zhenrong, Consulting Director of Life Sciences Business Unit in Greater China at Frost & Sullivan, was invited to attendPDD2024The Polypeptide Drug Industry Development Forum was held, during which speeches were delivered on the current status and development trends of the global polypeptide drug market.
Consulting Director, Life Sciences Business Unit, Frost & Sullivan Greater China Region Chen Zhenrong
Chen Zhenrong pointed out that with the rapid increase in approved weight loss indications and high consumer demand,2022GlobalGLP1RThe market scale of peptide drugs has reached254billions, expected to2030Annual or achievable908billion US dollars. The global peptide drug market has seen a significant increase in volume,2022The market scale has reached754billion dollars, inGLP1RUnder the continuous impact of peptide drugs, it is expected that the overall market scale of peptide drugs will reach2030Annual reach2,108billions, while the market scale of peptide drugs in China is also increasing year by year with the global market scale. It is expected that the Chinese market will become the main driving force for the global peptide drug market in the coming years, with the market scale accounting for a stable proportion of15%left and right.
Source: Analysis by Frost & Sullivan
Looking at the current development status of the global peptide drug market, Chen Zhenrong stated that the targets of peptide drugs are showing a diversified trend, not limited toGPL1RTargets, with increasingly diversified choices, will further drive the development of peptide drugs and continuously expand the scope of indications for these medications. In addition, as peptide drug products are approved, more related research and data are being disclosed.GLP1RTaking peptide drugs as an example, research has found that they not only have blood sugar regulation effects but also possess multiple metabolic regulatory functions such as weight loss and cardiovascular protection. These new findings will further promote the market's exploration of the multiple clinical benefits of peptide drug therapy.
"The Chinese peptide drug market started relatively late, and there are currently few approved domestic peptide new drugs. However, with the gradual improvement of China's peptide drug production industry chain, the Chinese peptide drugBEThe number of clinical trials conducted has risen rapidly, bringing development opportunities to many domestic generic drug manufacturers. Chen Zhenrong further pointed out that in recent years, our countryGLP1RThe growth rate of the peptide drug market has driven rapid expansion in China's peptide drug market. Due to China's large population base and widespread demand, while import product capacity is limited, there is still a significant gap on the demand side. For example, after the launch of semaglutide injection, there has been a shortage of supply. It is expected that with the approval of new products and generic drugs, the future development space of China's peptide drug market will be broad.
Source: Analysis by Frost & Sullivan
Chen Zhenrong stated that, driven by high demand, the Chinese peptide drug market has seen double growth in generic and innovative drugs, with continuously improving clinical acceptance. At the same time, specializationCRDMOIt will also strongly drive the continuous growth of China's peptide drug market, leading to industrial upgrading.
More exciting moments from the event arena
About Frost & Sullivan's Life Sciences Practice
The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan's global think tank resources and cross-industry business development platform in Greater China, the Life Sciences Practice has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice has a wide range of corporate clients in China and in the past20In the year, a vast customer network was established, accumulating a wealth of project experience in various subfields of life sciences.
Project types include Knowledge Center projects (in-depth content and promotional activities).Pre-IPO financingprojectDCF modelValuation, Business Plan Services),IPO listingWe provide listed projects (industry consulting, clinical audits, fundraising and investment writing), market research, market value management, and strategic consulting, among others. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to offer one-stop solutions for enterprises in specialized fields such as pharmaceuticals and medical devices. Our services have received widespread attention from investors.
